PS: Writing review & editing, Investigation, Writing original draft
Repurposing of long-acting FDA-approved GLP-1 receptor agonists such as semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple-agonist retatrutide which additionally targets glucagon receptors and is currently in clinical trials for obesity, may offer a promising strategy treating AUD
Heres the thing: fatigue can happen even during "successful" treatment
Others suggest that it facilitates weight loss and improves brain function
Highly recommend #biohacking #looksmaxing #antiaging #peptide #botox Peptides arent just a buzzword theyre a skin essential
Reduced anxiety and depression, which are common comorbidities of obesity, may contribute to enhanced libido and sexual satisfaction